Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
542
Recruiting Now
542
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT05265299 Phase 3
Recruiting
Trial to Determine Effective Aspirin Dose in COPD
Condition
Pulmonary Disease, Chronic Obstructive
Enrollment
48 pts
Location
United States
Sponsor
Johns Hopkins University
NCT07288398 Phase 3
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Condition
Pulmonary Hypertension Associated With HFpEF
Enrollment
540 pts
Location
United States, Argentina, Austria
Sponsor
Tenax Therapeutics, Inc.
NCT06882785 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japane...
Condition
Schizophrenia
Enrollment
250 pts
Location
Japan
Sponsor
Bristol-Myers Squibb
NCT05136976 Phase 3
Recruiting
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Character...
Condition
Anti-MAG Neuropathy
Enrollment
90 pts
Location
France
Sponsor
Centre Hospitalier Universitai
NCT06810791 Phase 3
Recruiting
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Condition
Newly Diagnosed Acute Myeloid Leukemia With High Risk
Enrollment
876 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med
NCT06393374 Phase 3
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did ...
Condition
Triple-Negative Breast Cancer
Enrollment
1,530 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT06630585 Phase 3
Recruiting
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Di...
Condition
Type 1 Diabetes (T1D)
Enrollment
42 pts
Location
Switzerland
Sponsor
University of Bern
NCT05586074 Phase 3
Recruiting
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Condition
Leukemia, Acute Myeloid (AML)
Enrollment
324 pts
Location
China
Sponsor
Sunshine Lake Pharma Co., Ltd.
NCT06737016 Phase 3
Recruiting
Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.
Condition
Posterior Urethral Valve
Enrollment
50 pts
Location
Egypt
Sponsor
Mansoura University
NCT07218926 Phase 3
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastr...
Condition
Gastrointestinal Neoplasms
Enrollment
450 pts
Location
United States, Australia, Belgium
Sponsor
GlaxoSmithKline
NCT07649525 Phase 3
Recruiting
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Tr...
Condition
Multiple Myeloma (MM)
Enrollment
1,226 pts
Location
United Kingdom
Sponsor
University of Leeds
NCT07507643 Phase 3
Recruiting
A Study of Methylprednisolone in People Having Liver Surgery
Condition
Hepatectomy
Enrollment
750 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT06941415 Phase 3
Recruiting
Bumetanide vs. Furosemide in Cirrhosis
Condition
Cirrhosis
Enrollment
500 pts
Location
United States
Sponsor
Stacy Johnson
NCT07361302 Phase 3
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke Whe...
Condition
Acute Ischemic Stroke
Enrollment
1,325 pts
Location
Argentina, Australia, Bulgaria
Sponsor
Boehringer Ingelheim
NCT05800223 Phase 3
Recruiting
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non...
Condition
Non-small Cell Lung Cancer Metastatic
Enrollment
300 pts
Location
China
Sponsor
Shanghai Cancer Hospital, Chin
NCT05920356 Phase 3
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab P...
Condition
Non-Small Cell Lung Cancer (NSCLC)
Enrollment
750 pts
Location
United States, Argentina, Australia
Sponsor
Amgen
NCT05880342 Phase 3
Recruiting
The Role of the Brain in Mental and Physical Fatigue
Condition
Fatigue
Enrollment
62 pts
Location
Belgium
Sponsor
Vrije Universiteit Brussel
NCT07436741 Phase 3
Recruiting
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclita...
Condition
Pancreatic Cancer, Adult
Enrollment
106 pts
Location
China
Sponsor
Tianjin Medical University Can
NCT07357051 Phase 3
Recruiting
Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy o...
Condition
Respiratory Viral Infection
Enrollment
177 pts
Location
China
Sponsor
Joincare Pharmaceutical Group
NCT06157502 Phase 3
Recruiting
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients ...
Condition
Ischemic Stroke, Acute
Enrollment
1,380 pts
Location
China
Sponsor
Beijing Tiantan Hospital
NCT07446439 Phase 3
Recruiting
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1...
Condition
Nausea and Vomiting
Enrollment
280 pts
Location
United States
Sponsor
Vanda Pharmaceuticals
NCT06152575 Phase 3
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in P...
Condition
Multiple Myeloma
Enrollment
492 pts
Location
United States, Argentina, Australia
Sponsor
Pfizer
NCT05470205 Phase 3
Recruiting
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewa...
Condition
Liver Diseases
Enrollment
660 pts
Location
United States, Switzerland
Sponsor
Thomas Jefferson University
NCT05735145 Phase 3
Recruiting
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advance...
Condition
Uterine Cervical Neoplasms
Enrollment
108 pts
Location
China
Sponsor
Fourth Affiliated Hospital of
NCT07087327 Phase 3
Recruiting
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Condition
Attention-Deficit Hyperactivity Disorder(ADHD)
Enrollment
180 pts
Location
Japan
Sponsor
Otsuka Pharmaceutical Co., Ltd
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology